[Danazol in the treatment of patients with combined pathology of endometrium and myometrium].
Forty-three patients aged 18 to 52 with combined diseases of the uterus and abnormal uterine bleedings were examined and followed up. The patients were prescribed danazon in a dose of 400 mg/day for 6 months to induce a short-term drug pseudomenopause. Immediate (in the cycle of drug discontinuation) and late (6 months after therapy discontinuation) results were assessed. A stable positive effect was observed in 12 women of premenopausal age over the course of 12-month follow-up; 10 patients were operated on for a recurrence of uterine bleedings and growth of uterine myomas. The mechanism of danazon effect on the female reproductive system and prospects of its use in diseases of the endo- and myometrium are discussed.
Vikhliaeva
E M
EM
Uvarova
E V
EV
Ishchenko
I G
IG
D000293:Adolescent; D000328:Adult; D003613:Danazol / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004717:Endometrium; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009215:Myometrium; D012008:Recurrence; D014591:Uterine Diseases / Q000188:drug therapy*; D014592:Uterine Hemorrhage / Q000188:drug therapy*
D003613:Danazol
Opyt primeneniia danazola u bolńykh s sochetannoĭ patologieĭ éndo- i miometriia.